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Anthony W.S. Chan,3 Chuan-Mu Chen,4 and Shang-Hsun Yang1,2,*
Huntington disease (HD) is a dominantly inherited neurodegenerative disorder characterized by dysregulation of various genes.
Recently, microRNAs (miRNAs) have been reported to be involved in this dysregulation, suggesting that manipulation of appropriate
miRNA regulationmay have a therapeutic benefit. Here, we report the beneficial effects of miR-196a (miR196a) on HD in cell, transgenic
mouse models, and human induced pluripotent stem cells derived from one individual with HD (HD-iPSCs). In the in vitro results, a
reduction of mutant HTT and pathological aggregates, accompanying the overexpression of miR-196a, was observed in HD models of
human embryonic kidney cells and mouse neuroblastoma cells. In the in vivo model, HD transgenic mice overexpressing miR-196a re-
vealed the suppression of mutant HTT in the brain and also showed improvements in neuropathological progression, such as decreases
of nuclear, intranuclear, and neuropil aggregates and late-stage behavioral phenotypes. Most importantly, miR-196a also decreased HTT
expression and pathological aggregates when HD-iPSCs were differentiated into the neuronal stage. Mechanisms of miR-196a in HD
might be through the alteration of ubiquitin-proteasome systems, gliosis, cAMP response element-binding protein pathway, and several
neuronal regulatory pathways in vivo. Taken together, these results show that manipulating miR-196a provides beneficial effects in HD,
suggesting the potential therapeutical role of miR-196a in HD.Huntington disease (HD [MIM 143100]) is an autosomal-
dominant disease that is caused by a mutation of CAG
trinucleotide repeats in the exon 1 region of the huntingtin
(HTT [MIM 613004]) gene.1 In principle, the longer the
CAG trinucleotide repeats, the earlier is onset of HD.
Pathological characteristics of HD include nuclear, intra-
nuclear, and neuropil aggregates and they lead to clinical
symptoms such as cognitive dysfunction, emotional
changes, mental deterioration, motor deficits, chorea,
and dystonia.2 Effective treatment of HD remains a
high-priority goal because effective therapies have not
emerged despite considerable insight into pathogenic
mechanisms.
Normally, endogenous HTT is involved in mechanisms
of gene regulation, suggesting that mutant HTT disrupts
physiological gene regulation in HD individuals.3 Re-
cently, posttranscriptional regulations by noncoding
RNAs, especially microRNAs (miRNAs), have been exten-
sively studied in central nervous system and neuronal dis-
eases,4,5 and there are indications that miRNAs might also
affect HD; however, there are still relatively few studies
investigating the relationship between miRNAs and HD.
Because HD is characterized by the dysfunction of several
mechanisms and one miRNA could target multiple path-
ways, this suggests that miRNA could be a potential treat-
ment for HD. We identify here that miR-196a (MIM
608632) has a potential effect on HD and further confirm
that increased expression of miR-196a ameliorates the mo-1Department of Physiology, College of Medicine, National Cheng Kung Univ
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in vitro and in vivo.
Based on the results of a miRNA microarray study by
Packer et al. in 20086 and our unpublished microarray
data with the brain tissues of HD transgenic monkeys,
miR-196a was identified as a possible candidate for
involvement in the pathogenesis of HD. To study the ef-
fects of miR-196a on HD in vitro, we transfected miR-
196a mimics or inhibitors (Genepharma) with mutant
HTT into 293 FT (human embryonic kidney cells) and
N2a (mouse neuroblastoma cells) cells. Because a direct
degradation of mRNA through the complementary disrup-
tion between miR-196a and the coding region of our trans-
gene is one possible mechanism leading to a lower expres-
sion of themutantHTT transgene, we aligned sequences of
miR-196a and the coding region of our transgene and
confirmed that there was no complementary sequence
(data not shown), suggesting that the expression of
mutant HTT might not be through a direct degradation
of mRNA. In the transfection experiments, we observed
that miR-196a mimics suppressed the expression of
mutant HTT compared to that of an unrelated control, as
shown by immunoblotting with mEM48 against mutant
HTT (Figure 1A). In addition, we also examined the RNA
expression level of miR-196a (Figures S1A and S1C avail-
able online) and mutant HTT (Figures S1B and S1D) via
real-time reverse-transcription quantitative PCR (qRT-
PCR) and observed that a higher expression of miR-196aersity, Tainan 70101, Taiwan; 2Institute of Basic Medical Sciences, National
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Figure 1. miR-196a Suppressed the Expression of Mutant HTT In Vitro
293 FT and N2a cells were transfected with miR-196a mimics, miR-196a inhibitors, unrelated controls (NC), and mutant HTT (GHD) as
indicated in different graphs. Expression of mutant HTT was analyzed 48 hr after transfection.
(A) Immunoblotting by mEM48 showed lower expression of mutant HTT at either high (stacking gel) or low (separating gel) molecular
weight in 293 FT (left) and N2a (right) cells transfected with miR-196a and GHD. g-tubulin (Sigma) was used as an internal control.
(B) Immunoblotting results showed that transfected 293 FT cells with MG-132 (Enzo Life Sciences) treatment did not obviously alter
expression profiles of mutant HTT, whereas anisomycin (Enzo Life Sciences) suppressed the expression of aggregated HTT, suggesting
that miR-196 suppressed the expression of mutant HTT through the suppression of protein synthesis predominantly and protein degra-
dation partly.
(C) Fluorescent signals of mutant HTT were detected via GFP fusion proteins in 293 FT (top) and N2a (bottom) cells. Under the same
exposure condition, cells transfected with miR-196a and GHD showed lower fluorescence signal. These images were merged with trans-
mission light, and arrows indicate intranuclear aggregates.
(D) Top panel shows the miR-196a construct containing the ubiquitin promoter to drive miR-196a precursor and red fluorescence pro-
tein (dsRED), respectively, and the mutant HTT construct containing the ubiquitin promoter to drive HD84Q fused with GFP. Abbrevi-
ations are as follows:WPRE, woodchunk hepatitis virus posttranscriptional regulatory element; FLAP, human immunodeficiency virus-1
falp element; LTR, long terminal repeat. Bottompanel shows the expression ofmutant HTT (green) and the expression ofmiR-196a (red),
suggesting the suppression of mutant HTT.could significantly suppress the mRNA level of mutant
HTT in two cell lines. These results suggest that miR-196a
can suppress the mRNA and protein expression of mutant
HTT in vitro and that the process is not through a direct
degradation of mutant HTT mRNA.
However, because we used human ubiquitin promoter to
drive the mutant HTT gene,7,8 there remains a question of
whether miR-196a affected the ubiquitin promoter rather
than the expression of mutant HTT. Therefore, different
promoters, including cytomegalovirus (CMV) and endoge-
nous human HTT promoters, were constructed to explore
this question (Figure S2A), and the results also showedThe Amerrepression of mutant HTT (Figures S2B and S2C). This sug-
gests that miR-196a suppressed the expression of mutant
HTT, not the expression of an ubiquitin promoter.
The next question is whether miR-196a functions
through the inhibition of mutant HTT synthesis or
through the acceleration of degradation. We therefore
treated 293 FT cells with either 1 mM MG-132 (a protea-
some inhibitor) or 0.1 mM anisomycin (a protein synthesis
inhibitor) when miR-196a and mutant HTT were cotrans-
fected. Upon treatment with MG-132, a stronger signal
was observed in the miR-196a group compared to that of
miR-NC, whereas no aggregated protein was observed inican Journal of Human Genetics 93, 306–312, August 8, 2013 307
Figure 2. miR-196a Suppressed the Expression of Mutant HTT in HD Transgenic Mouse Model
(A) Top panel shows the construct of mutant HTT and miR-196a used for the generation of GHD transgenic mice. Bottom left shows the
suppression of mutant HTT mRNA determined by qRT-PCR (Applied Biosystems) using brain samples of different transgenic mice at
1 month of age (n ¼ 6–8 for each group). Bottom right shows the immunoblotting, with suppression of mutant HTT in the brains of
D-Tg transgenic mice at 1 month of age compared to those of GHD transgenic mice. mEM48 was used to detect mutant HTT, and
g-tubulin was used as the internal control. Asterisk represents significant difference between two groups.
(B) Immunoblotting shows the suppression of mutant HTT in the brains of D-Tg transgenic mice at 1 (left) and 12 (right) months of age.
One brain sample of a wild-typemouse (WT) was used as a negative control. N2a cells transfected withmutantHTT (N2aGHD)were used
as a positive control, and wild-type N2a cells (N2a WT) were used as a negative control of cells.
(C) Improvement of neuropathological phenotypes in brains of D-Tg mice at 12 months of age via a mEM48 antibody (n ¼ 3–5 mice).
Top three images show significant neuropil (stars), nuclear (arrows), and intranuclear (arrowheads) aggregates in different brain regions
from one representative GHD transgenic mouse, including striatum (STR), cortex (CTX), and white matter (WM), via a 3, 30-diamino-
bezidine (DAB) method (Vector Laboratories). Bottom three images show brain pathology from one representative D-Tg transgenic
mouse.
(D) Quantitation figures show accumulated number of nuclear, intranuclear, and neuropil aggregates via theMetaMorph software. Accu-
mulated number of aggregates was counted in five random1203 120 mM2 regions. Asterisk represents significant difference between two
groups.
(E) Improvement of behavioral phenotypes in D-Tgmice at 12months of age. Clasping, grasping (Bioseb), rotarod (Singa), and footprint-
ing tests were performed at 12 months of age in four groups (n ¼ 6–9 mice for each group). Data represent mean5 SD, and different
characters on different bars indicate statistically significant difference.either group after anisomycin treatment (Figure 1B). This
result suggests that miR-196 suppressed the expression of
mutant HTT predominantly through the suppression of
protein synthesis and partly through protein degradation.
Furthermore, because a fusion protein, green fluorescent
protein (GFP), was constructed in the 50 end of mutant
HTT in this study, fluorescent signals could be used to indi-
cate the expression of mutant HTT. Under the same expo-
sure conditions, weaker fluorescent signals were detected
in 293 FT and N2a cells treated with miR-196a mimics308 The American Journal of Human Genetics 93, 306–312, August 8(Figure 1C). In addition, different fluorescent reporter
genes were cloned into the vector system (Figure 1D,
top), and the results showed a reduction of mutant HTT
along with a higher expression of miR-196a (Figure 1D,
bottom). These in vitro results taken together suggested a
suppression ability of miR-196a on HTT in vitro.
In order to further study the effects of miR-196a in vivo,
miR-196a transgenic mice (196a) were generated via lenti-
viral transgenesis (Figure 2A, top)7 and then bred withGFP-
HTT (GHD) transgenic mice8 (Figure 2A, top) to obtain, 2013
four groups of mice: double transgenic mice (D-Tg) car-
rying mutant HTT and miR-196a, GHD transgenic mice,
196a transgenic mice, and wild-type (WT) mice. All animal
procedures performed in this study were approved by the
Institutional Animal Care and Use Committees at National
Cheng Kung University. Tests for HTT mRNA and protein
in brain samples of D-Tg and GHD transgenic mice at
1 month of age showed lower expression levels of mutant
HTT in D-Tg transgenic mice compared to those of GHD
transgenic mice (Figure 2A, bottom). We also confirmed
the significantly higher expression of miR-196a in D-Tg
transgenic mice compared to that of GHD transgenic
mice (Figure S3). Because HD is a progressive disease result-
ing from the continuous accumulation of mutant HTT,2
the suppression ability of miR-196a at different stages
was examined. Immunoblotting results from brain sam-
ples taken from D-Tg and GHD transgenic mice at 1 and
12months of age showed an increase of aggregatedmutant
HTT in GHDmice at 12 months of age, whereas D-Tg mice
displayedmuch fewermutant HTTat either 1 or 12months
of age (Figure 2B), implying that miR-196a can inhibit the
expression of mutant HTT in vivo.
Accumulation of mutant HTT leads to neuropatholog-
ical phenotypes, such as neuropil aggregates, nuclear ag-
gregates, and intranuclear aggregates, in the brains of HD
models.2,8 Therefore, pathological features in these mice
were examined. In GHD transgenic mice at 12 months
of age, severe pathological aggregates were observed in
different brain regions, such as the cortex and striatum
(Figure 2C, top), whereas much fewer aggregates were
observed in D-Tg transgenic mice (Figure 2C, bottom).
These results were also confirmed through computational
quantitation (Figure 2D), revealing that miR-196a had
significantly alleviated pathological phenotypes in vivo.
Gradual deterioration of behavioral phenotypes is an
important symptom for HD, especially motor functions.2
Therefore, four longitudinal examinations, including
clasping, grasping, rotarod, and footprinting tests, were
performed in mice. At 4 and 8 months of age, comparable
behavioral phenotypes were observed (Figure S4); how-
ever, deteriorated performance was observed in GHD
mice at 12 months of age, whereas D-Tg mice showed a
similar performance to that of 196a and WT mice
(Figure 2E). Taken together, these studies in mice indicate
that miR-196a can alleviate molecular, pathological, and
behavioral phenotypes in vivo.
Because the above HD transgenic mice constitute an
overexpression model, we were curious about the effects
of miR-196a on human endogenous HTT. The model of
HD individual-derived induced pluripotent stem cells
(HD-iPSCs) is a unique platform to study endogenous
HTT in HD research.9,10 Therefore, we used HD-iPSCs
(GM23225) purchased and permitted from the Coriell
Institute in this study and differentiated these cells into
neuronal cells. As HD-iPSCs were differentiated into
neuronal cells in N3medium,miR-196a and empty lentivi-
ruses were used to infect these differentiated cellsThe Amer(Figure 3A). Because it is difficult to induce pathological
phenotypes in HD-iPSCs, 10 mM MG-132 (a proteasome
inhibitor) was added to accelerate the accumulation of
mutant HTT. First, we confirmed the characteristics of
HD-iPSCs at different stages, demonstrating that these cells
carrying 72 CAG repeats could successfully differentiate
into neuronal cells (Figures 3B and 3C). Immunostaining
via a mEM48 antibody was performed 30 hr after MG-
132 treatments, revealing certain signals of aggregates in
empty vector group compared to that in miR-196a group
(Figure 3D). Immunoblotting also revealed a lower expres-
sion level of mutant HTT in the miR-196a group via
mEM48 and MAB2166 antibodies (Figure 3E), suggesting
that miR-196a could suppress the expression of mutant
HTT and alleviate the pathological phenotypes in human
samples.
Because miR-196a can suppress the expression of
mutant HTT both in vitro and in vivo, the detailed mech-
anisms should therefore be addressed. Based on online
bioinformatic analysis (TargetScan 6.2), HTT is not the
target gene of miR-196a, suggesting that miR-196a influ-
ences HD through other indirect pathways. The impair-
ment of protein clearance pathways, such as the ubiqui-
tin-proteasome system (UPS), in HD11 led us to examine
the UPS in brain samples, which showed a clear decrease
of high-molecular-weight unibiquitin protein in D-Tg
transgenic mice compared to that of GHD transgenic
mice (Figure 4A). Also, because reactive gliosis is an impor-
tant manifestation of damage to the central nervous sys-
tem in brains of HD,12 we therefore assessed the profiling
of glial fibrillary acidic protein (GFAP; a marker represent-
ing reactive gliosis) in these mice, and the results showed
a decrease of GFAP (Figure 4A) and less-reactive gliosis in
D-Tg brains (Figure 4B). Furthermore, a decrease of
calmodulin kinase II (CaMKII) activity has been reported
in HD models, leading to an impairment of the cAMP
response element-binding protein (CREB) pathway.13,14
Therefore, we also determined the total CaMKII and phos-
phorylated CaMKII (pCaMKII) in the brain samples, and
the results showed that D-Tg transgenic mice reverted to
higher expression levels of pCaMKII (Figure 4C). However,
UPS and CaMKII results in infected HD-iPSCs were to
some extent different to the in vivo mouse model
(Figure S5). This might be due to the difference between
in vitro and in vivo systems and might also be due to
the different severity of pathological aggregates in these
two models.
In addition, microarray analyses (Phalanx Biotech
Group) of the striatum from D-Tg and GHD transgenic
mice via MetaCore (GeneGo) revealed that several genes
related to neuronal functions, such as dendritic spine
morphogenesis, neurotransmitter transport, and neurolog-
ical system processes, had been altered (Figure 4D). We also
analyzed genes from both TargetScan 6.2 and our microar-
ray with the MetaCore software and observed that several
genes from the two data sets are involved in CREB, gliosis,
and UPS pathways (Table S1), suggesting that miR-196aican Journal of Human Genetics 93, 306–312, August 8, 2013 309
Figure 3. miR-196a Suppressed Pathological Aggregates in HD-iPSCs
(A) Schematic of experimental design for differentiating HD-iPSCs into neuronal cells.
(B) PCR was used to confirm 72 and 17 CAG repeats inside HD-iPSCs, showing 309 and 144 bp of amplicons.
(C) Immunostaining indicated that undifferentiated HD-iPSCs (ALP [Bio SB] and Oct4 [GeneTex]) differentiated into neuronal precursor
stage (Nestin; GeneTex) and neuronal stage (b-III tubulin; Millipore).
(D) Differentiated HD-iPSCs treated with control viruses (FUW; top) displayed pathological aggregates (arrows), whereas cells treated
with miR-196a viruses (196a; bottom) did not.
(E) Immunoblotting by mEM48 and Huntingtin (Chemicon; MAB2166) antibodies showed weaker HTT fragments in the 196a cells
compared to those of the FUW group. g-tubulin was used as an internal control.might function through these TargetScan 6.2-predicted
genes to affect these three pathways. In addition, we
observed that three predicted genes, E3 ubiquitin-protein
ligase NEDD4-like (MIM 606384), E3 ubiquitin-protein ligase
RNF5 (MIM 602677), and Ubiquitin carboxyl-terminal
hydrolase 15 (MIM 604731), were downregulated in D-Tg
mice in the microarray data (Table S1), suggesting that
miR-196a might function through destabilizing the
mRNAs of these three genes and subsequently affect the
UPS pathway. However, further evidence is needed. Taken
together, these results suggest that miR-196a might
alleviate phenotypes of HD in vivo via improvement of
UPS, gliosis, CREB pathway, and several neuronal regu-
latory pathways.
A higher expression of miR-196a in HDmodels has been
reported in the microarray database;6,15 however, overex-
pression of miR-196a can alleviate HD both in vitro and
in vivo in our study, implying that a higher expression of
miR-196a might be caused by HD and that the expression
level of miR-196a in the above HD models might be too
low to provide protective functions. In several disease
models, miR-196a has offered beneficial effects, including310 The American Journal of Human Genetics 93, 306–312, August 8hepatitis C (MIM 609532)16 and spinal and bulbar
muscular atrophy (SBMA [MIM 313200]).17 Moreover,
miR-196a also plays critical roles such as in gene regula-
tion, nuclear architecture, antiapoptosis, and calcium
binding.18 Therefore, whether miR-196a provides neuro-
protective effects on HD through similar regulatory mech-
anisms should be further investigated.
Although miR-196a has multiple predicted targets, HTT
is not one of them,19 suggesting that miR-196a does not
alleviate HD directly through targeting mutant HTT. One
direct target, CUGBP Elav-like family member 2 (CELF2
[MIM 602538]), has attracted our attention because
CELF2 can be regulated by miR-196a in SBMA, another
neurodegenerative disease characterized by the expansion
of CAG repeats in the mutant androgen receptor (AR [MIM
313700]) gene.17 Because of the binding of CELF2 to the
mRNA of expanded CAG repeats in SBMA,17 we strongly
suspected a role for CELF2 in HD. However, we did not
observe a lower expression level of CELF2 either in HD
293 FT cells transfected with miR-196a or in our mouse
model (Figure S6A). In addition, we also tested whether
CELF2 bound to the mRNA of mutant HTT via RNA, 2013
Figure 4. Improvement of D-Tg Transgenic Mice Was through Several Different Mechanisms
Brain samples from GHD and D-Tg transgenic mice at 12 months of age were subjected to immunoblotting, immunohistochemical
staining, and microarray analyses.
(A) Higher expression level of ubiquitin (DakoCytomation) and GFAP (Sigma) proteins in GHD transgenic mice compared to those of
D-Tg transgenic mice upon immunoblotting.
(B) Immunohistochemical staining showed ameliorated gliosis in the different brain regions, including striatum (STR), cortex (CTX), and
white matter (WM), of D-Tg transgenic mice (bottom) compared to those of GHD transgenic mice (top).
(C) Immunoblotting showed a higher expression level of pCaMKII (Abcam) in D-Tg transgenicmice compared to that in GHD transgenic
mice.
(D) Candidate genes showing significant alternation between D-Tg and GHD transgenic mice were obtained from microarray analyses.immunoprecipitation and observed that precipitated
CELF2 did not bind more mutant HTT mRNA compared
to that of the IgG control (Figure S6B). This suggests that
CELF2 might not be involved in the mechanism of miR-
196a on HD, and so other candidates should be screened.
Of particular interest for further research is the question
of whether miR-196a could also have beneficial effects in
other polyglutamine diseases.
In summary, a higher expression of miR-196a not
only reduced the expression of mutant HTT in vitro but
also improved molecular, pathological, and behavioral
phenotypes in a HD transgenic mouse model. Most
importantly, miR-196a ameliorated the formation of
pathological aggregates in HD-iPSCs differentiating into
the neuronal stage. We further show that the effects of
miR-196a might be through the alteration of the ubiqui-
tin-proteasome systems, gliosis, and the CREB pathway.
This study suggests the important role of miR-196a in
HD and provides an insight into a therapeutical strategy
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